The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Multiple Myeloma
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294-3300
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States, 85234
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States, 72205
UCLA Hematology/Oncology - Westwood (Building 200 Suite 214), Los Angeles, California, United States, 90095
UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco, California, United States, 94143
Colorado Blood Cancer Institute, Denver, Colorado, United States, 80218
Local Institution - 0062, Jacksonville, Florida, United States, 32224
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States, 33176
Moffitt Cancer Center, Tampa, Florida, United States, 33612
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States, 30322
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2032-06-30